10x Genomics, Inc. Q2 2026 Earnings Recap

The 9.6% stock jump reflects strong investor enthusiasm for the Atera platform, which drove robust order flow and broad customer engagement beyond initial expectations.

Key Takeaways

• Q2 revenue was $151 million, including $1.6 million in non-recurring settlement revenue; organic revenue grew 3% year-over-year to $149 million.
• Atera launch generated unusually high early demand, with customers across academia and biopharma adopting the platform for diverse research applications including oncology and neurodegeneration.
• Strong growth in Chromium consumable reaction volumes and continued exceptional utilization of the Xenium spatial platform contributed to underlying strength.
• Catalyst Research Services, offering sample processing on Atera, has attracted strong interest as a flexible entry point for customers without immediate instrument access.
• Acquisition of Proteintech Genomics is expected to enhance Atera’s multi-omics capabilities, particularly in proteomics integration.